Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

[18F]FDG, [11C]PiB, and [18F]AV-1451 PET Imaging of Neurodegeneration in Two Subjects With a History of Repetitive Trauma and Cognitive Decline.

Okonkwo DO, Puffer RC, Minhas DS, Beers SR, Edelman KL, Sharpless J, Laymon CM, Lopresti BJ, Benso S, Puccio AM, Pathak S, Ikonomovic MD, Mettenburg JM, Schneider W, Mathis CA, Mountz JM.

Front Neurol. 2019 Aug 2;10:831. doi: 10.3389/fneur.2019.00831. eCollection 2019.

2.

The Impact of Arterial Input Function Determination Variations on Prostate Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Modeling: A Multicenter Data Analysis Challenge, Part II.

Huang W, Chen Y, Fedorov A, Li X, Jajamovich GH, Malyarenko DI, Aryal MP, LaViolette PS, Oborski MJ, O'Sullivan F, Abramson RG, Jafari-Khouzani K, Afzal A, Tudorica A, Moloney B, Gupta SN, Besa C, Kalpathy-Cramer J, Mountz JM, Laymon CM, Muzi M, Kinahan PE, Schmainda K, Cao Y, Chenevert TL, Taouli B, Yankeelov TE, Fennessy F, Li X.

Tomography. 2019 Mar;5(1):99-109. doi: 10.18383/j.tom.2018.00027.

3.

Complementary Molecular and Metabolic Characterization of Meningiomas With DOTATATE and FDG-PET: Advancing Treatment Planning and Prognostication.

Dressen MS, Muthukrishnan A, Tragon TR, Lieberman FS, Mountz JM.

Clin Nucl Med. 2019 Jan;44(1):e26-e27. doi: 10.1097/RLU.0000000000002328.

PMID:
30371576
4.

The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective.

Press RH, Shu HG, Shim H, Mountz JM, Kurland BF, Wahl RL, Jones EF, Hylton NM, Gerstner ER, Nordstrom RJ, Henderson L, Kurdziel KA, Vikram B, Jacobs MA, Holdhoff M, Taylor E, Jaffray DA, Schwartz LH, Mankoff DA, Kinahan PE, Linden HM, Lambin P, Dilling TJ, Rubin DL, Hadjiiski L, Buatti JM.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1219-1235. doi: 10.1016/j.ijrobp.2018.06.023. Epub 2018 Jun 30. Review.

5.

Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study.

Nguyen NC, Yee MK, Tuchayi AM, Kirkwood JM, Tawbi H, Mountz JM.

Front Oncol. 2018 Feb 22;8:18. doi: 10.3389/fonc.2018.00018. eCollection 2018.

6.

Image-Based 2D Re-Projection for Attenuation Substitution in PET Neuroimaging.

Laymon CM, Minhas DS, Becker CR, Matan C, Oborski MJ, Price JC, Mountz JM.

Mol Imaging Biol. 2018 Oct;20(5):826-834. doi: 10.1007/s11307-018-1171-5.

PMID:
29488191
7.

Preclinical Evaluation of 18F-ML-10 to Determine Timing of Apoptotic Response to Chemotherapy in Solid Tumors.

Demirci E, Ahmed R, Ocak M, Latoche J, Radelet A, DeBlasio N, Mason NS, Anderson CJ, Mountz JM.

Mol Imaging. 2017 Jan 1;16:1536012116685941. doi: 10.1177/1536012116685941.

8.

Pediatric Epilepsy: Neurology, Functional Imaging, and Neurosurgery.

Mountz JM, Patterson CM, Tamber MS.

Semin Nucl Med. 2017 Mar;47(2):170-187. doi: 10.1053/j.semnuclmed.2016.10.003. Epub 2016 Nov 10. Review.

PMID:
28237005
9.

Multi-site quality and variability analysis of 3D FDG PET segmentations based on phantom and clinical image data.

Beichel RR, Smith BJ, Bauer C, Ulrich EJ, Ahmadvand P, Budzevich MM, Gillies RJ, Goldgof D, Grkovski M, Hamarneh G, Huang Q, Kinahan PE, Laymon CM, Mountz JM, Muzi JP, Muzi M, Nehmeh S, Oborski MJ, Tan Y, Zhao B, Sunderland JJ, Buatti JM.

Med Phys. 2017 Feb;44(2):479-496. doi: 10.1002/mp.12041.

10.

Accrual Patterns for Clinical Studies Involving Quantitative Imaging: Results of an NCI Quantitative Imaging Network (QIN) Survey.

Kurland BF, Aggarwal S, Yankeelov TE, Gerstner ER, Mountz JM, Linden HM, Jones EF, Bodeker KL, Buatti JM.

Tomography. 2016 Dec;2(4):276-282. doi: 10.18383/j.tom.2016.00169.

11.

[18F]ML-10 PET: Initial Experience in Glioblastoma Multiforme Therapy Response Assessment.

Oborski MJ, Laymon CM, Lieberman FS, Qian Y, Drappatz J, Mountz JM.

Tomography. 2016 Dec;2(4):317-324. doi: 10.18383/j.tom.2016.00175.

12.

Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation.

Nguyen NC, Shah M, Appleman LJ, Parikh R, Mountz JM.

Int J Mol Imaging. 2016;2016:2568031. Epub 2016 Sep 27. Review.

13.

Repeatability of 18F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma.

Lodge MA, Holdhoff M, Leal JP, Bag AK, Nabors LB, Mintz A, Lesser GJ, Mankoff DA, Desai AS, Mountz JM, Lieberman FS, Fisher JD, Desideri S, Ye X, Grossman SA, Schiff D, Wahl RL.

J Nucl Med. 2017 Mar;58(3):393-398. doi: 10.2967/jnumed.116.178434. Epub 2016 Sep 29.

14.

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.

Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Weiss GJ, Sachdev JC, Chadha M, Fulk M, Ejadi S, Mountz JM, Lotze MT, Toledo FG, Chu E, Jeffers M, Peña C, Xia C, Reif S, Genvresse I, Ramanathan RK.

Ann Oncol. 2016 Oct;27(10):1928-40. doi: 10.1093/annonc/mdw282.

15.

The Impact of Arterial Input Function Determination Variations on Prostate Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Modeling: A Multicenter Data Analysis Challenge.

Huang W, Chen Y, Fedorov A, Li X, Jajamovich GH, Malyarenko DI, Aryal MP, LaViolette PS, Oborski MJ, O'Sullivan F, Abramson RG, Jafari-Khouzani K, Afzal A, Tudorica A, Moloney B, Gupta SN, Besa C, Kalpathy-Cramer J, Mountz JM, Laymon CM, Muzi M, Schmainda K, Cao Y, Chenevert TL, Taouli B, Yankeelov TE, Fennessy F, Li X.

Tomography. 2016 Mar;2(1):56-66.

16.

Quantitative Imaging in Cancer Clinical Trials.

Yankeelov TE, Mankoff DA, Schwartz LH, Lieberman FS, Buatti JM, Mountz JM, Erickson BJ, Fennessy FM, Huang W, Kalpathy-Cramer J, Wahl RL, Linden HM, Kinahan PE, Zhao B, Hylton NM, Gillies RJ, Clarke L, Nordstrom R, Rubin DL.

Clin Cancer Res. 2016 Jan 15;22(2):284-90. doi: 10.1158/1078-0432.CCR-14-3336. Review.

17.

Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia.

Eisenmenger LB, Huo EJ, Hoffman JM, Minoshima S, Matesan MC, Lewis DH, Lopresti BJ, Mathis CA, Okonkwo DO, Mountz JM.

Semin Nucl Med. 2016 Jan;46(1):57-87. doi: 10.1053/j.semnuclmed.2015.09.003. Review.

PMID:
26687858
18.

Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.

Mountz JM, Laymon CM, Cohen AD, Zhang Z, Price JC, Boudhar S, McDade E, Aizenstein HJ, Klunk WE, Mathis CA.

Neuroimage Clin. 2015 Oct 14;9:592-8. doi: 10.1016/j.nicl.2015.10.007. eCollection 2015.

19.

In vivo brain rosette spectroscopic imaging (RSI) with LASER excitation, constant gradient strength readout, and automated LCModel quantification for all voxels.

Schirda CV, Zhao T, Andronesi OC, Lee Y, Pan JW, Mountz JM, Hetherington HP, Boada FE.

Magn Reson Med. 2016 Aug;76(2):380-90. doi: 10.1002/mrm.25896. Epub 2015 Aug 26.

20.

PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis.

Chen RY, Dodd LE, Lee M, Paripati P, Hammoud DA, Mountz JM, Jeon D, Zia N, Zahiri H, Coleman MT, Carroll MW, Lee JD, Jeong YJ, Herscovitch P, Lahouar S, Tartakovsky M, Rosenthal A, Somaiyya S, Lee S, Goldfeder LC, Cai Y, Via LE, Park SK, Cho SN, Barry CE 3rd.

Sci Transl Med. 2014 Dec 3;6(265):265ra166. doi: 10.1126/scitranslmed.3009501.

21.

Quantifying metabolic heterogeneity in head and neck tumors in real time: 2-DG uptake is highest in hypoxic tumor regions.

Nakajima EC, Laymon C, Oborski M, Hou W, Wang L, Grandis JR, Ferris RL, Mountz JM, Van Houten B.

PLoS One. 2014 Aug 15;9(8):e102452. doi: 10.1371/journal.pone.0102452. eCollection 2014.

22.

Short-T2 imaging for quantifying concentration of sodium (23 Na) of bi-exponential T2 relaxation.

Qian Y, Panigrahy A, Laymon CM, Lee VK, Drappatz J, Lieberman FS, Boada FE, Mountz JM.

Magn Reson Med. 2015 Jul;74(1):162-174. doi: 10.1002/mrm.25393. Epub 2014 Jul 30.

23.

Letter to cancer center directors: Progress in quantitative imaging as a means to predict and/or measure tumor response in cancer therapy trials.

Mountz JM, Yankeelov TE, Rubin DL, Buatti JM, Erikson BJ, Fennessy FM, Gillies RJ, Huang W, Jacobs MA, Kinahan PE, Laymon CM, Linden HM, Mankoff DA, Schwartz LH, Shim H, Wahl RL.

J Clin Oncol. 2014 Jul 1;32(19):2115-6. doi: 10.1200/JCO.2014.55.8866. Epub 2014 May 27. No abstract available.

24.

Variations of dynamic contrast-enhanced magnetic resonance imaging in evaluation of breast cancer therapy response: a multicenter data analysis challenge.

Huang W, Li X, Chen Y, Li X, Chang MC, Oborski MJ, Malyarenko DI, Muzi M, Jajamovich GH, Fedorov A, Tudorica A, Gupta SN, Laymon CM, Marro KI, Dyvorne HA, Miller JV, Barbodiak DP, Chenevert TL, Yankeelov TE, Mountz JM, Kinahan PE, Kikinis R, Taouli B, Fennessy F, Kalpathy-Cramer J.

Transl Oncol. 2014 Feb 1;7(1):153-66. eCollection 2014 Feb.

25.

Challenges and Approaches to Quantitative Therapy Response Assessment in Glioblastoma Multiforme Using the Novel Apoptosis Positron Emission Tomography Tracer F-18 ML-10.

Oborski MJ, Laymon CM, Qian Y, Lieberman FS, Nelson AD, Mountz JM.

Transl Oncol. 2014 Feb 1;7(1):111-9. eCollection 2014 Feb.

26.

Errors in Quantitative Image Analysis due to Platform-Dependent Image Scaling.

Chenevert TL, Malyarenko DI, Newitt D, Li X, Jayatilake M, Tudorica A, Fedorov A, Kikinis R, Liu TT, Muzi M, Oborski MJ, Laymon CM, Li X, Thomas Y, Jayashree KC, Mountz JM, Kinahan PE, Rubin DL, Fennessy F, Huang W, Hylton N, Ross BD.

Transl Oncol. 2014 Feb 1;7(1):65-71. eCollection 2014 Feb.

27.

Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods.

Ahmed R, Oborski MJ, Hwang M, Lieberman FS, Mountz JM.

Cancer Manag Res. 2014 Mar 24;6:149-70. doi: 10.2147/CMAR.S54726. eCollection 2014. Review.

28.

First use of (18)F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapy.

Oborski MJ, Laymon CM, Lieberman FS, Drappatz J, Hamilton RL, Mountz JM.

Brain Behav. 2014 Mar;4(2):312-5. doi: 10.1002/brb3.217. Epub 2014 Feb 12.

29.

Use of 111In-pentetreotide scan in a subject with treatment refractory atypical meningioma.

Bural GG, Lieberman F, Mountz JM.

Clin Nucl Med. 2014 Apr;39(4):342-5. doi: 10.1097/RLU.0000000000000326.

PMID:
24445268
30.

Assessment of early therapy response with 18F-FLT PET in glioblastoma multiforme.

Oborski MJ, Demirci E, Laymon CM, Lieberman FS, Mountz JM.

Clin Nucl Med. 2014 Oct;39(10):e431-2. doi: 10.1097/RLU.0000000000000321.

PMID:
24368529
31.

Molecular and metabolic pattern classification for detection of brain glioma progression.

Imani F, Boada FE, Lieberman FS, Davis DK, Mountz JM.

Eur J Radiol. 2014 Feb;83(2):e100-5. doi: 10.1016/j.ejrad.2013.06.033. Epub 2013 Nov 20.

32.

Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis.

Carroll MW, Jeon D, Mountz JM, Lee JD, Jeong YJ, Zia N, Lee M, Lee J, Via LE, Lee S, Eum SY, Lee SJ, Goldfeder LC, Cai Y, Jin B, Kim Y, Oh T, Chen RY, Dodd LE, Gu W, Dartois V, Park SK, Kim CT, Barry CE 3rd, Cho SN.

Antimicrob Agents Chemother. 2013 Aug;57(8):3903-9. doi: 10.1128/AAC.00753-13. Epub 2013 Jun 3.

33.
34.

Clinical value of the first dedicated, commercially available automatic injector for ictal brain SPECT in presurgical evaluation of pediatric epilepsy: comparison with manual injection.

Kim S, Holder DL, Laymon CM, Tudorascu DL, Deeb EL, Panigrahy A, Mountz JM.

J Nucl Med. 2013 May;54(5):732-8. doi: 10.2967/jnumed.112.105189. Epub 2013 Mar 14.

35.

Improved Benefit of SPECT/CT Compared to SPECT Alone for the Accurate Localization of Endocrine and Neuroendocrine Tumors.

Bural GG, Muthukrishnan A, Oborski MJ, Mountz JM.

Mol Imaging Radionucl Ther. 2012 Dec;21(3):91-6. doi: 10.4274/Mirt.80299. Epub 2012 Dec 20.

36.

Nuclear imaging of a pregnant patient: should we perform nuclear medicine procedures during pregnancy?

Bural GG, Laymon CM, Mountz JM.

Mol Imaging Radionucl Ther. 2012 Apr;21(1):1-5. doi: 10.4274/Mirt.123. Epub 2012 Apr 1.

37.

Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches.

Cohen AD, Mowrey W, Weissfeld LA, Aizenstein HJ, McDade E, Mountz JM, Nebes RD, Saxton JA, Snitz B, Dekosky S, Williamson J, Lopez OL, Price JC, Mathis CA, Klunk WE.

Neuroimage. 2013 May 1;71:207-15. doi: 10.1016/j.neuroimage.2013.01.015. Epub 2013 Jan 24.

38.

A semi-quantitative method for correlating brain disease groups with normal controls using SPECT: Alzheimer's disease versus vascular dementia.

Chen YJ, Deutsch G, Satya R, Liu HG, Mountz JM.

Comput Med Imaging Graph. 2013 Jan;37(1):40-7. doi: 10.1016/j.compmedimag.2012.11.001. Epub 2012 Dec 27.

PMID:
23273615
39.

Advances in the diagnosis and treatment of epilepsy.

Tamber MS, Mountz JM.

Semin Nucl Med. 2012 Nov;42(6):371-86. doi: 10.1053/j.semnuclmed.2012.06.005. Review.

PMID:
23026360
40.

Brain tumors.

Herholz K, Langen KJ, Schiepers C, Mountz JM.

Semin Nucl Med. 2012 Nov;42(6):356-70. doi: 10.1053/j.semnuclmed.2012.06.001. Review.

41.

Guest editorial: the future of nuclear medicine in the management of CNS diseases.

Mountz JM.

Semin Nucl Med. 2012 Nov;42(6):354-5. doi: 10.1053/j.semnuclmed.2012.08.001. No abstract available.

PMID:
23026358
42.

Emerging optical and nuclear medicine imaging methods in rheumatoid arthritis.

Mountz JM, Alavi A, Mountz JD.

Nat Rev Rheumatol. 2012 Dec;8(12):719-28. doi: 10.1038/nrrheum.2012.148. Epub 2012 Sep 25. Review.

PMID:
23007740
43.

Promise and pitfalls of quantitative imaging in oncology clinical trials.

Kurland BF, Gerstner ER, Mountz JM, Schwartz LH, Ryan CW, Graham MM, Buatti JM, Fennessy FM, Eikman EA, Kumar V, Forster KM, Wahl RL, Lieberman FS.

Magn Reson Imaging. 2012 Nov;30(9):1301-12. doi: 10.1016/j.mri.2012.06.009. Epub 2012 Aug 13. Review.

44.

Combined imaging biomarkers for therapy evaluation in glioblastoma multiforme: correlating sodium MRI and F-18 FLT PET on a voxel-wise basis.

Laymon CM, Oborski MJ, Lee VK, Davis DK, Wiener EC, Lieberman FS, Boada FE, Mountz JM.

Magn Reson Imaging. 2012 Nov;30(9):1268-78. doi: 10.1016/j.mri.2012.05.011. Epub 2012 Jul 21.

45.

Informatics methods to enable sharing of quantitative imaging research data.

Levy MA, Freymann JB, Kirby JS, Fedorov A, Fennessy FM, Eschrich SA, Berglund AE, Fenstermacher DA, Tan Y, Guo X, Casavant TL, Brown BJ, Braun TA, Dekker A, Roelofs E, Mountz JM, Boada F, Laymon C, Oborski M, Rubin DL.

Magn Reson Imaging. 2012 Nov;30(9):1249-56. doi: 10.1016/j.mri.2012.04.007. Epub 2012 Jul 6.

46.

Intermittent cystocele diagnosed on 18F-FDG PET/CT scan.

Mountz JM, Bural GG.

Clin Nucl Med. 2012 May;37(5):e108-9. doi: 10.1097/RLU.0b013e31824853c9.

PMID:
22475919
47.

Benign epithelial cyst mimicking thyroid cancer metastasis: a false-positive finding on post-therapy I-131 scan.

Bural GG, Peel RL, Mountz JM.

Clin Nucl Med. 2012 Jan;37(1):88-90. doi: 10.1097/RLU.0b013e31822920a3. No abstract available.

PMID:
22157038
48.

Tc-99m red blood cell bleeding scan in a pregnant woman presenting with hematemesis: a brief review of indications and guidelines for radionuclide scans during pregnancy.

Bural GG, Scheetz M, Laymon CM, Mountz JM.

Clin Nucl Med. 2011 Nov;36(11):987-90. doi: 10.1097/RLU.0b013e3182291a2d. Review.

PMID:
21975385
49.

SPECT Imaging of Epilepsy: An Overview and Comparison with F-18 FDG PET.

Kim S, Mountz JM.

Int J Mol Imaging. 2011;2011:813028. doi: 10.1155/2011/813028. Epub 2011 Jul 14.

50.

Noninvasive assessment of cell proliferation in ovarian cancer using [18F] 3'deoxy-3-fluorothymidine positron emission tomography/computed tomography imaging.

Richard SD, Bencherif B, Edwards RP, Elishaev E, Krivak TC, Mountz JM, DeLoia JA.

Nucl Med Biol. 2011 May;38(4):485-91. doi: 10.1016/j.nucmedbio.2010.12.003. Epub 2011 Mar 3.

PMID:
21531285

Supplemental Content

Loading ...
Support Center